Answers are grounded in this paper and cite their sources.
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer-related deaths, leading to poor responses to chemotherapy. Cancer-related pain affects up to 90% of these patients, significantly impairing their quality of life. Tramadol, a prescribed analgesic for cancer pain, has shown anti-tumour effects in various malignancies, yet its potential in HCC remains largely unexplored. In this study, we investigated tramadol's anti-proliferative, pro-apoptotic, and autophagy-inducing effects in HepG2, Hep3B, and Huh7 cell lines. Tramadol significantly inhibits cell proliferation in a dose-dependent manner, leading to a reduction in the S-phase and subG1 phase accumulation. It induces apoptosis in HepG2 and Hep3B, increases late apoptosis/necrosis, and enhances autophagy. Additionally, tramadol increased the cytotoxicity of cisplatin and 5-fluorouracil, with significant reductions in their IC50 values. Overall, tramadol inhibits HCC growth, promotes apoptosis, and enhances chemotherapy efficacy, suggesting it could be a dual-benefit therapeutic strategy for HCC.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: